-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The safety and efficacy of live viral vaccines, such as the varicella-zoster vaccine, in patients with inflammatory diseases receiving immunomodulatory
therapy, such as tumor necrosis factor inhibitors (TNFis), are unknown .
A study published in Ann Intern Med evaluated the safety and immunogenicity of live attenuated varicella vaccine (ZVL) in patients treated with TNFis
immunity
Using a randomized, blinded, placebo-controlled design, adults 50 years of age and older receiving TNFis were randomized to ZVL versus placebo
.
Glycoproteinase-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent assay (ELISpot) of serum and peripheral blood mononuclear cells were measured at baseline and 6 weeks after vaccination
Infect
RESULTS: From March 2015 to December 2018, a total of 617 participants were included in the study, randomized 1:1 to receive ZVL (n = 310) or placebo (n = 307) at 33 centers
.
Mean age was 62.
rheumatoid arthritis
Taken together, the findings provide evidence for the safety of live virus vaccines in patients receiving biologics
.
A limitation of the study is that generalizability to patients receiving other types of immunomodulators may be limited
Original source:
Jeffrey R Curtis, et al.
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial
leave a message here